Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A multicentre dose-response study

Hepatology Research

Volumn 13, Issue 1, 1998, Pages 10-19

  Crosignani, Andrea ^a   Battezzati, Pier Maria ^a   Cestari, Cristina ^a   Stabilini, Roberto ^a   Conte, Dario ^a   Zappalà, Francesco ^b   Floreani, Annarosa ^b   Montalto, Giuseppe ^c   Soresi, Maurizio ^c   Notarbartolo, Alberto ^c   Buscarini, Elisabetta ^d   Buscarini, Luigi ^d   Buongiorno, Giampiero ^e   Manghisi, Onofrio Giuseppe ^e   Podda, Mauro ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d Hospital of Piacenza   (Italy)

^e NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Bile acids; Chronic hepatitis; Dose response relationship; Liver disease; Tauroursodeoxycholic acid; Therapy

Indexed keywords

AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; TAUROURSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032415992     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(98)00070-9     Document Type: Article

References (30)

1. Podda M, Ghezzi C, Battezzati PM et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci. 34:1989;59S-65.
2. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. New Engl J Med. 324:1991;1548-1554.
3. Heathcote EJ, Cauch-Dudek K, Walker V et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19:1994;1149-1156.
4. Lindor KD, Dickson ER, Baldus WP et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 106:1994;1284-1290.
5. Combes B, Carithers RL Jr, Maddrey WC et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 22:1995;759-766.
6. Poupon RR, Poupon R, Balkau B Ursodiol for long-term treatment of primary biliary cirrhosis. New Engl J Med. 330:1994;1342-1347.
7. Armstrong MJ, Carey MC The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res. 23:1982;70-80.
8. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L. Bile acid induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses. 19:1986;57-69.
9. Hofmann AF, Popper H. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet. ii:1987;398-399.
10. Akashi Y, Miyazaki H, Yanagisawa J, Nakayama F. Bile acid metabolism in cirrhotic liver tissue: altered synthesis and impaired hepatic secretion. Clin Chim Acta. 2:1987;199-206.
11. Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci. 30:1985;642-649.
12. Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology. 98:1990;1044-1050.
13. Crosignani A, Battezzati PM, Setchell KDR et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis; a dose-response study. Hepatology. 13:1991;339-344.
14. Takano S, Ito Y, Yokosuka O et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology. 20:1994;558-564.
15. Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. Eur J Clin Pharmacol. 40:1991;473-476.
16. Bellentani S, Podda M, Tiribelli C et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol. 19:1993;459-464.
17. Attili AF, Rusticali A, Varriale M, Carli L, Repice AM The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. J Hepatol. 20:1994;315-320.
18. Nakamura K, Yoneda M, Tamori K et al. Effect of ursodeoxycholic acid (UDCA) on patients with type I autoimmune hepatitis. Gastroenterology. 108:1995;1129A.
19. Mima S, Sekiya C, Kanagawa H, Uchida T Ursodeoxycholic acid (UDCA) therapy for autoimmune hepatitis. Int Hepatol Comm. 2:1994;207-212.
20. Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR Tauroursodeoxycholic acid is more effective than ursodeoxycholic acid in increasing liver ursodeoxycholate concentrations and reducing lithocholate formation in the rats. Gastroenterology. 109:1995;564-572.
21. Setchell KDR, Rodrigues CPM, Podda M, Crosignani A Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut. 38:1996;439-446.
22. Portincasa P, Palmieri V, Doronzo F et al. Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis. Curr Ther Res. 53:1993;521-532.
23. Furio L, Tomaiuolo P, Gatta R et al. Treatment of virus-associated liver cirrhosis with tauroursodeoxycholic acid: evaluation of cytolysis and cholestasis indexes and selected immunologic variables. Curr Ther Res. 55:1994;1355-1362.
24. Notarbartolo A, Montalto G, Soresi M, Bascone F Tauroursodeoxycholic acid in patients with chronic hepatitis C: effect on serum levels of transaminases and gamma glutamyl transpeptidase. Adv Ther. 11:1994;262-268.
25. Angelico M, Del Vecchio C, Nistri A Effect of tauroursodeoxycholic acid on serum liver enzyme and serum lipid levels in patients with chronic active hepatitis. Curr Ther Res. 56:1995;626-634.
26. Conover WJ, Iman RL Rank transformations as a bridge between parametric and nonparametric studies. Am Stat. 35:1981;124-129.
27. Nakai T, Katagiri K, Hoshino N, Hayakawa T, Ohiwa T Microtubule-independent choleresis and anti-cholestatic action of tauroursodeoxycholate in colchicine treated rat liver. Biochem J. 288:1992;613-617.
28. Tsukahara K, Kanai S, Ohta M, Kitani K Taurine conjugate of ursodeoxycholate plays a major role in the hepatoprotective effect against cholestasis induced by taurochenodeoxycholate in rats. Liver. 13:1993;262-269.
29. Crosignani A, Battezzati PM, Setchell KDR et al. Tauroursodeoxycholic acid for the treatment of primary biliary cirrhosis: a dose-response study. Dig Dis Sci. 41:1996;809-815.
30. Crosignani A, Setchell KDR, Invernizzi P, Larghi A, Rodrigues CMP, Podda M Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet. 30:1996;333-358.